What the FDA labels say about taking them together
Captopril and temsirolimus
Captopril's FDA label of February 6, 2026 names temsirolimus in its warnings section; temsirolimus's label does not name captopril itself but warns about its class (ACE inhibitors). The captopril label: “Information for Patients and ADVERSE REACTIONS.) Patients receiving coadministration of ACE inhibitor and mTOR inhibitor therapy or a neprilysin inhibitor may be at increased risk for angioedema.”
Check it at the source: the captopril FDA label on DailyMed (effective February 6, 2026, AiPing Pharmaceutical, Inc.); the temsirolimus FDA label on DailyMed (effective December 26, 2025, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.).
What does the captopril label say about temsirolimus?
Captopril label, warningsInformation for Patients and ADVERSE REACTIONS .) Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin inhibitor may be at increased risk for angioedema (see PRECAUTIONS, Drug Interactions ).
Source: FDA drug label (Captopril), AiPing Pharmaceutical, Inc., effective February 6, 2026 (SPL set 3b789f16-b291-4012-be39-af3beec3ff9a), via openFDA; the full label on DailyMed
What does the temsirolimus label say about captopril?
Temsirolimus's label does not name captopril itself; it warns about its class (ACE inhibitors):
Temsirolimus label, drug interactionsIf alternative treatment cannot be administered, a dose adjustment should be considered [see Dosage and Administration (2.4) ]. Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine.
Temsirolimus label, drug interactionsMonitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).
Source: FDA drug label (Torisel), NDA022088 (Pf Prism Cv), as published by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective December 26, 2025 (SPL set 95b7dc92-2180-42f1-8699-3c28f609e674), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Captopril | Temsirolimus | |
|---|---|---|
| Labeled for | High blood pressure, Heart failure, Chronic kidney disease | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $0.228 per tablet 12.5 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once